Barclays PLC Raises Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

Barclays PLC grew its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 182.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 195,793 shares of the medical instruments supplier’s stock after acquiring an additional 126,503 shares during the quarter. Barclays PLC owned about 0.26% of OraSure Technologies worth $836,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of OSUR. Atom Investors LP purchased a new stake in shares of OraSure Technologies during the third quarter valued at $49,000. Creative Planning purchased a new stake in OraSure Technologies during the 3rd quarter valued at about $54,000. Mackenzie Financial Corp acquired a new position in shares of OraSure Technologies in the second quarter valued at about $72,000. Intech Investment Management LLC acquired a new stake in shares of OraSure Technologies during the third quarter worth about $84,000. Finally, SkyView Investment Advisors LLC boosted its position in OraSure Technologies by 100.0% in the second quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 12,000 shares during the last quarter. 93.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Monday, December 9th.

OraSure Technologies Stock Performance

NASDAQ OSUR opened at $3.61 on Wednesday. The firm has a market capitalization of $269.28 million, a P/E ratio of 24.07 and a beta of 0.03. The stock has a 50-day simple moving average of $3.94 and a two-hundred day simple moving average of $4.15. OraSure Technologies, Inc. has a fifty-two week low of $3.52 and a fifty-two week high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $39.92 million during the quarter, compared to the consensus estimate of $38.97 million. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. OraSure Technologies’s revenue for the quarter was down 55.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.27 earnings per share. As a group, analysts forecast that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.